Safety evaluation of biological drugs: What are toxicology studies in primates telling us?-Reference-Cited by-同舟云学术

Safety evaluation of biological drugs: What are toxicology studies in primates telling us?

Published:2011-03 Issue:2 Volume:59 Page:227-236
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Baldrick Paul

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference29 articles.

1. Safety evaluation to support First-In-Man investigations II: toxicology studies;Baldrick;Regul. Toxicol. Pharmacol.,2008

2. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys;Boon;Toxicology,2002

3. Pharmacokinetics/ADME of large molecules;Braeckman,2005

4. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies;Brennan;mAbs,2010

5. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans;Bugelski;Curr. Opin. Mol. Ther.,2004

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of weight-of-evidence approaches to characterize developmental toxicity risk for therapeutic monoclonal antibodies in humans without in vivo studies;Regulatory Toxicology and Pharmacology;2024-09

2. Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex;Frontiers in Pharmacology;2023-09-12

3. How important are concurrent vehicle control groups in (sub)chronic non-human primate toxicity studies conducted in pharmaceutical development? An opportunity to reduce animal numbers;PLOS ONE;2023-08-03

4. How important are concurrent vehicle control groups in (sub)chronic non-human primate toxicity studies conducted in pharmaceutical development? An opportunity to reduce animal numbers;2023-02-16

5. The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain;Regulatory Toxicology and Pharmacology;2023-02